5F-MDMB-PICA |
|
| Other names | 5F-MDMB-2201; 5-Fluoro MDMB-PICA |
|---|
|
| Legal status |
|
|---|
|
Methyl (2S)-2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| KEGG | |
|---|
|
| Formula | C21H29FN2O3 |
|---|
| Molar mass | 376.472 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
O=C(N[C@H](C(OC)=O)C(C)(C)C)C1=CN(CCCCCF)C2=C1C=CC=C2
|
InChI=1S/C21H29FN2O3/c1-21(2,3)18(20(26)27-4)23-19(25)16-14-24(13-9-5-8-12-22)17-11-7-6-10-15(16)17/h6-7,10-11,14,18H,5,8-9,12-13H2,1-4H3,(H,23,25)/t18-/m1/s1 Key:CHSUEEBESACQDV-GOSISDBHSA-N
|
5F-MDMB-PICA (MDMB-5F-PICA[2]) is a designer drug and synthetic cannabinoid.[3][4][5][6][7] In 2018, it was the fifth-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.[8]
5F-MDMB-PICA is a potent agonist of both the CB1 receptor and the CB2 receptor with EC50 values of 0.45 nM and 7.4 nM, respectively.[9]
In the United States, 5F-MDMB-PICA was temporarily emergency scheduled by the DEA in 2019.[10] In December 2019, the UNODC announced scheduling recommendations placing 5F-MDMB-PICA into Schedule II.[11] In the United States 5F-MDMB-PICA was made a permanent Schedule I Controlled Substance nationwide on April 7, 2022.[12]
References
- ^ Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
- ^ Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403. PMID 36346325. S2CID 253396419.
- ^ Risseeuw MD, Blanckaert P, Coopman V, Van Quekelberghe S, Van Calenbergh S, Cordonnier J (April 2017). "Identification of a new tert-leucinate class synthetic cannabinoid in powder and "spice-like" herbal incenses: Methyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate (5F-MDMB-PICA)". Forensic Science International. 273: 45–52. doi:10.1016/j.forsciint.2017.01.023. hdl:1854/LU-8542830. PMID 28214755.
- ^ Mogler L, Franz F, Rentsch D, Angerer V, Weinfurtner G, Longworth M, et al. (January 2018). "Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples". Drug Testing and Analysis. 10 (1): 196–205. doi:10.1002/dta.2201. PMID 28371476.
- ^ Szpot P, Nowak K, Wachełko O, Tusiewicz K, Chłopaś-Konowałek A, Zawadzki M (January 2023). "Methyl (S)-2-(1-7 (5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (5F-MDMB-PICA) intoxication in a child with identification of two new metabolites (ultra-high-performance liquid chromatography-tandem mass spectrometry)". Forensic Toxicology. 41 (1): 47–58. doi:10.1007/s11419-022-00629-7. PMID 36652054. S2CID 249318941.
- ^ Tokarczyk B, Jurczyk A, Krupińska J, Adamowicz P (December 2022). "Fatal intoxication with new synthetic cannabinoids 5F-MDMB-PICA and 4F-MDMB-BINACA-parent compounds and metabolite identification in blood, urine and cerebrospinal fluid". Forensic Science, Medicine, and Pathology. 18 (4): 393–402. doi:10.1007/s12024-022-00492-3. PMC 9194349. PMID 35699867.
- ^ Wagmann L, Stiller RG, Fischmann S, Westphal F, Meyer MR (October 2022). "Going deeper into the toxicokinetics of synthetic cannabinoids: in vitro contribution of human carboxylesterases". Archives of Toxicology. 96 (10): 2755–2766. doi:10.1007/s00204-022-03332-z. PMC 9352624. PMID 35788413.
- ^ "Emerging Threat Report: Annual 2018" (PDF). Special Testing and Research Laboratory, Drug Enforcement Administration. Archived from the original (PDF) on 2019-08-01. Retrieved 2019-08-02.
- ^ Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al. (September 2016). "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience. 7 (9): 1241–1254. doi:10.1021/acschemneuro.6b00137. PMID 27421060.
- ^ "Schedules of Controlled Substances: Temporary Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 into Schedule I". Federal Register. 2019-04-16.
- ^ "December 2019 – WHO: World Health Organization recommends 12 NPS for scheduling".
- ^ "Schedules of Controlled Substances: Placement of 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA, and FUB-144 in Schedule I" (PDF). Federal Register. 87 (67). 2022-04-07.
Further reading
|
|---|
Phytocannabinoids (comparison) | | Cannabibutols | |
|---|
| Cannabichromenes | |
|---|
| Cannabicyclols | |
|---|
| Cannabidiols | |
|---|
| Cannabielsoins | |
|---|
| Cannabigerols | |
|---|
| Cannabiphorols | |
|---|
| Cannabinols |
- CBN
- CBNA
- CBN-C1
- CBN-C2
- CBN-C4
- CBNM
- CBND
- CBNP
- CBVD
|
|---|
| Cannabitriols | |
|---|
| Cannabivarins | |
|---|
| Delta-3-tetrahydrocannabinols | |
|---|
| Delta-4-tetrahydrocannabinols | |
|---|
| Delta-7-tetrahydrocannabinols | |
|---|
| Delta-8-tetrahydrocannabinols |
- Delta-8-THC
- Delta-8-THCB
- Delta-8-THCP
- Delta-8-THCV
|
|---|
| Delta-9-tetrahydrocannabinols | |
|---|
| Delta-10-Tetrahydrocannabinols | |
|---|
| Delta-11-Tetrahydrocannabinols | |
|---|
| Miscellaneous cannabinoids | |
|---|
| Active metabolites | |
|---|
|
|---|
| Endocannabinoids | |
|---|
Synthetic cannabinoid receptor agonists / neocannabinoids | Classical cannabinoids (dibenzopyrans) | |
|---|
Non-classical cannabinoids |
- Cannabicyclohexanol
- Cannabinor
- CBD-DMH
- CP 47,497
- (C6)-CP 47,497
- (C9)-CP 47,497
- CP 55,244
- CP 55,940
- Delta-6-Cannabidiol
- Etrinabdione
- HU-320
- HU-331
- HU-336
- HU-345
- HU-446
- HU-465
- HU-910
- HUF-101
- Nonabine
- O-1376
- O-1422
- O-1601
- O-1656
- O-1657
- O-1660
- O-1663
- O-1871
- Onternabez (HU-308)
- SPA-229
- Tinabinol
|
|---|
| Adamantoylindoles | |
|---|
| Benzimidazoles |
- AZ-11713908
- AZD-1940
- BIM-018
- FUBIMINA
- MCHB-1
- PF-03550096
- RQ-00202730
|
|---|
| Benzoylindoles |
- 1-Butyl-3-(2-methoxybenzoyl)indole
- 1-Butyl-3-(4-methoxybenzoyl)indole
- 1-Pentyl-3-(2-methoxybenzoyl)indole
- AM-630
- AM-679
- AM-694
- AM-1241
- AM-2233
- GW-405,833 (L-768,242)
- Pravadoline
- RCS-4
- WIN 54,461
|
|---|
| Cyclohexylphenols | |
|---|
| Eicosanoids |
- AM-883
- AM-1346
- ACEA
- ACPA
- Methanandamide (AM-356)
- O-585
- O-689
- O-1812
- O-1860
- O-1861
|
|---|
Indazole-3- carboxamides | |
|---|
| Indole-3-carboxamides |
- 4'F-CUMYL-5F-PICA
- 5F-ADBICA
- 5F-EDMB-PICA
- 5F-NNE1
- 5F-PCN
- 5F-SDB-006
- AB-FUBICA
- AB-PICA
- ADBICA
- ADB-FUBICA
- APICA
- BMS-F
- CUMYL-BICA
- CUMYL-CBMICA
- CUMYL-CHMICA
- CUMYL-NBMICA
- CUMYL-PICA
- CUMYL-5F-PICA
- FDU-NNE1
- MDMB-CHMICA
- MMB-CHMICA
- MMB-2201
- MN-25 (UR-12)
- NNE1
- PX-1
- Org 28312
- Org 28611
- SDB-006
- STS-135
|
|---|
| Indole-3-carboxylates | |
|---|
| Naphthoylindazoles | |
|---|
| Naphthoylindoles |
- 5F-JWH-398
- AM-1220
- AM-1221
- AM-1235
- AM-2201
- AM-2232
- CHM-081
- EAM-2201
- FUB-JWH-018
- JWH-004
- JWH-007
- JWH-009
- JWH-011
- JWH-015
- JWH-016
- JWH-018
- JWH-019
- JWH-020
- JWH-042
- JWH-043
- JWH-046
- JWH-047
- JWH-048
- JWH-049
- JWH-050
- JWH-070
- JWH-072
- JWH-073
- JWH-076
- JWH-077
- JWH-079
- JWH-080
- JWH-081
- JWH-082
- JWH-083
- JWH-093
- JWH-094
- JWH-095
- JWH-096
- JWH-097
- JWH-098
- JWH-099
- JWH-100
- JWH-116
- JWH-120
- JWH-122
- JWH-148
- JWH-149
- JWH-151
- JWH-153
- JWH-159
- JWH-160
- JWH-163
- JWH-164
- JWH-165
- JWH-166
- JWH-180
- JWH-181
- JWH-182
- JWH-189
- JWH-193
- JWH-198
- JWH-200
- JWH-210
- JWH-211
- JWH-212
- JWH-213
- JWH-234
- JWH-235
- JWH-236
- JWH-239
- JWH-240
- JWH-241
- JWH-242
- JWH-258
- JWH-259
- JWH-260
- JWH-261
- JWH-262
- JWH-265
- JWH-266
- JWH-267
- JWH-268
- JWH-387
- JWH-398
- JWH-416
- JWH-417
- JWH-422
- JWH-423
- JWH-424
- JWH-425
- MAM-1220
- MAM-2201
- NE-CHMIMO
|
|---|
| Naphthoylpyrroles |
- JWH-030
- JWH-031
- JWH-032
- JWH-033
- JWH-036
- JWH-044
- JWH-045
- JWH-145
- JWH-146
- JWH-147
- JWH-150
- JWH-156
- JWH-243
- JWH-244
- JWH-245
- JWH-246
- JWH-292
- JWH-293
- JWH-307
- JWH-308
- JWH-309
- JWH-346
- JWH-347
- JWH-348
- JWH-363
- JWH-364
- JWH-365
- JWH-366
- JWH-367
- JWH-368
- JWH-369
- JWH-370
- JWH-371
- JWH-372
- JWH-373
|
|---|
| Naphthylmethylindenes | |
|---|
| Naphthylmethylindoles |
- JWH-175
- JWH-184
- JWH-185
- JWH-192
- JWH-194
- JWH-195
- JWH-196
- JWH-197
- JWH-199
|
|---|
| Phenylacetylindoles |
- Cannabipiperidiethanone
- JWH-167
- JWH-201
- JWH-202
- JWH-203
- JWH-204
- JWH-205
- JWH-206
- JWH-207
- JWH-208
- JWH-209
- JWH-237
- JWH-248
- JWH-249
- JWH-250
- JWH-251
- JWH-252
- JWH-253
- JWH-302
- JWH-303
- JWH-304
- JWH-305
- JWH-306
- JWH-311
- JWH-312
- JWH-313
- JWH-314
- JWH-315
- JWH-316
- RCS-8
|
|---|
| Pyrazolecarboxamides |
- 5F-AB-FUPPYCA
- 5F-AMPPPCA
- AB-CHFUPYCA
|
|---|
Tetramethylcyclo- propanoylindazoles | |
|---|
Tetramethylcyclo- propanoylindoles | |
|---|
| Others |
- 2F-QMPSB
- 4-HTMPIPO
- 4CN-CUMYL-BUT7AICA
- 5F-3-pyridinoylindole
- 5F-ADB-P7AICA
- 5F-CUMYL-P7AICA
- 5F-CUMYL-PEGACLONE
- 5F-PY-PICA
- 5F-PY-PINACA
- A-836,339
- A-955,840
- A-PBITMO
- A-PONASA
- AB-001
- ADB-FUBHQUCA
- ADB-FUBIATA
- ADB-P7AICA
- AM-1248
- AM-1714
- Abnormal cannabidiol
- BAY 38-7271
- BAY 59-3074
- BzODZ-EPyr
- CB-13
- CB-86
- CBS-0550
- CUMYL-4CN-B7AICA
- CUMYL-CB-MEGACLONE
- CUMYL-CH-MEGACLONE
- CUMYL-PEGACLONE
- Cis-THC
- EG-018
- GSK-554,418A
- GW-842,166X
- HHCP-O-acetate
- HHCH
- Iso-THC
- JTE 7-31
- LASSBio-881
- LBP-1
- Leelamine
- MDA-19
- MDA-7
- MEPIRAPIM
- NESS-040C5
- NMDMSB
- NMP-7
- O-1269
- O-1270
- O-1399
- O-1602
- O-2220
- O-889
- Olorinab
- PF-03550096
- PSB-SB-1202
- PTI-1
- PTI-2
- PTI-3
- QMPSB
- S-444,823
- S-777,469
- SER-601
- THCP-O-acetate
- Tedalinab
- URB-447
- VSN-16
- Vicasinabin
- WIN 55,212-2
- WIN 56,098
|
|---|
|
|---|
| Allosteric CBRTooltip Cannabinoid receptor ligands |
- AEF0117
- GAT100
- Org 27569
- Org 27759
- Org 29647
- PSNCBAM-1
- Pregnenolone
- RTI-371
- ZCZ-011
|
|---|
Endocannabinoid enhancers (inactivation inhibitors) | |
|---|
Anticannabinoids (antagonists/inverse agonists/antibodies) |
- ABD459
- AM-251
- AM-281
- AM-630
- AM-1387
- AM-4113
- AM-6527
- AM-6545
- Amauromine
- ANEB-001
- AZD-2207
- BML-190
- CAY-10508
- CB-25
- CB-52
- CB-86
- CE-178253
- COR170
- Drinabant (AVE1625)
- Hemopressin
- Ibipinabant (SLV319)
- JD-5037
- JTE-907
- LH-21
- LY-320,135
- MDA-77
- MJ-15
- MK-9470
- Monlunabant
- MRL-650
- NESS-0327
- NIDA-41020
- O-606
- O-1184
- O-1248
- O-1918
- O-2050
- O-2654
- Otenabant (CP-945,598)
- PF-514273
- PGN36
- PipISB
- PSB-SB-487
- Rezosicone
- Rimonabant (SR141716)
- Rosonabant (E-6776)
- SLV 319
- SR-144,528
- Surinabant (SR147778)
- Taranabant (MK-0364)
- TC-C 14G
- TM-38837
- VCHSR
- Voacamine
- Zevaquenabant
|
|---|
- See also: Cannabinoid receptor modulators (cannabinoids by pharmacology)
- List of: AM cannabinoids
- JWH cannabinoids
- Designer drugs § Synthetic cannabimimetics
|